PDS Biotechnology Corporation (PDSB)

NASDAQ: PDSB · Real-Time Price · USD
1.650
-0.100 (-5.71%)
At close: Dec 20, 2024, 4:00 PM
1.760
+0.110 (6.67%)
After-hours: Dec 20, 2024, 6:33 PM EST
-5.71%
Market Cap 61.73M
Revenue (ttm) n/a
Net Income (ttm) -40.56M
Shares Out 37.41M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 570,749
Open 1.750
Previous Close 1.750
Day's Range 1.630 - 1.808
52-Week Range 1.530 - 6.680
Beta 1.84
Analysts Strong Buy
Price Target 14.00 (+748.49%)
Earnings Date Nov 14, 2024

About PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunolog... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 25
Stock Exchange NASDAQ
Ticker Symbol PDSB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 748.49% from the latest price.

Price Target
$14.0
(748.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...

16 days ago - GlobeNewsWire

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prev...

19 days ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer...

5 weeks ago - Seeking Alpha

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...

6 weeks ago - GlobeNewsWire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully  treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete ...

2 months ago - GlobeNewsWire

PDS Biotechnology: Continuing The Holding Pattern

PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipelin...

3 months ago - Seeking Alpha

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...

3 months ago - GlobeNewsWire

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...

3 months ago - GlobeNewsWire

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...

4 months ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

PDS Biotechnology Corporation (NASDAQ:PDSB) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Offi...

5 months ago - Seeking Alpha

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.

5 months ago - GlobeNewsWire

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...

5 months ago - GlobeNewsWire

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

7 months ago - GlobeNewsWire

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (...

8 months ago - GlobeNewsWire

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...

8 months ago - GlobeNewsWire

PDS Biotechnology Announces Details of Virtual KOL Event

Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated ...

8 months ago - GlobeNewsWire

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...

8 months ago - GlobeNewsWire

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial

8 months ago - GlobeNewsWire

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial

9 months ago - GlobeNewsWire

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline ...

9 months ago - GlobeNewsWire

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants

10 months ago - GlobeNewsWire

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data

Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is exp...

11 months ago - Seeking Alpha

PDS Biotech Announces Retirement of Lauren V. Wood, M.D.

Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hemat...

11 months ago - GlobeNewsWire

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline o...

1 year ago - GlobeNewsWire